REPLIGEN CORP Decrease in Restricted Cash
REPLIGEN CORP (RGEN) reported Decrease in Restricted Cash of $450.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Notes
us-gaap:DecreaseInRestrictedCash · last filed 2018-02-22
- REPLIGEN CORP decrease in restricted cash for fiscal 2017 was $450.00K.
| Period end | Decrease in Restricted Cash 12 month |
|---|---|
| 2017-12-31 | $450.00K 10-K · filed 2018-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |